

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 May 2005 (06.05.2005)


PCT

(10) International Publication Number
WO 2005/040222 A1

- (51) International Patent Classification⁷: C07K 16/38, G01N 33/53
- (21) International Application Number: PCT/US2004/024881
- (22) International Filing Date: 29 July 2004 (29.07.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/511,835 16 October 2003 (16.10.2003) US
- (71) Applicant (for all designated States except US): BAYER HEALTHCARE LLC [US/US]; 555 White Plains Road, Tarrytown, NY 10591 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): PUGIA, Michael, J. [US/US]; 14342 Taddington Dr., Granger, IN 46530 (US). ANDERSON-MAUSER, Linda [US/US]; 60438 CR 3, Elkhart, IN 46517 (US). MURPHY, Solomon, H. [US/US]; 295 E. Lasalle Avenue, Apt. 301a, South Bend, IN 46617 (US). SOMMER, Ronald, G. [US/US]; 55745 Merle Street, Elkhart, Indiana 46514 (US). GLEASON, Shannon [US/US]; 14006 Carter Lake Street, Jones, MI 49061 (US).
- (74) Agent: WELLS, Harold, N.; Jenkens & Gilchrist, a Professional Corporation, 225 W. Washington Street, Suite 2600, Chicago, IL 60606-3418 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:
— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- Published:
— with international search report

[Continued on next page]

(54) Title: MONOCLONAL ANTIBODIES FOR DETECTION OF URINARY TRYPSIN INHIBITORS



(57) Abstract: Certain monoclonal antibodies are able to detect urinary trypsin inhibitors (UTIs) that are characteristic of disease in humans. In particular, the UTIs include AMBK, Bikunin, Uristatin, Uristatin-1, Uristatin-2, as defined herein, also including the fragments and aggregates thereof.

WO 2005/040222 A1



-
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

MONOCLONAL ANTIBODIES FOR DETECTION OF URINARY TRYPSIN INHIBITORS

Background of the Invention

This invention relates generally to the detection of urinary trypsin inhibitors (UTIs) in human urine. UTIs inhibit one or more of the Serine proteases. Trypsin is a member of the family of Serine proteases, i.e. enzymes, that includes trypsin, elastase, kallikrein, plasmin, thrombin, chymotrypsin, and cathepsin, among others. This group of inhibitors primarily forms after an increase in the number of white blood cells in the body due to the release of elastase during infection or inflammation. UTIs are not normally found in the urine produced by healthy individuals. The amount is elevated in those whose bodies have bacterial infections and inflammatory disorders or other maladies such as malignant tumors, kidney disease, myocardial infarction, lung emphysema, surgical trauma, and kidney stones among others.

When infections and/or inflammation occur, the bodies' response involves the production of serine proteases such as elastase released by neutrophils. Non-inhibitor forms of UTI, called pro-inhibitors, such as interleukin- α -inhibitor (I- α -I) and the pre-interleukin- α -inhibitor (P- α -I), circulate freely in plasma of healthy and diseased individuals. Serine proteases cause proteolysis of the pro-inhibitors and release the lower molecular weight UTIs into active function. The released urinary trypsin inhibitors act on serine proteases and are later excreted in the urine. Discovered in 1909, urine trypsin inhibitors are Kunitz-type protease inhibitors and have been named HI-30, Mingin, Urinastatin, Serpin, and Ulinastatin over the years with the scientific community settling on the name Bikunin for a prevalent fragment of ~30 Kda molecular weight. The amino acid sequence of the Bikunin inhibitor fragment is known. It contains two Kunitz inhibitory binding domains and a large and variable chondroitin sulfate chain. See the International Journal of Biochemistry and Cell Biology 32 (2000) 125-137.

Although the amount of urinary trypsin inhibitors has been measured by several methods, e.g. enzyme inhibition, antibody stains, latex agglutination, and radioimmunoassays, all of the UTIs in the sample are measured. It has not been shown that certain forms of the inhibitor can result from chronic disease and are more easily distinguished from the inhibitors which were present in individuals with lesser degrees of inflammation. As a result, the diagnostic use of UTIs has to date only been as a non-

specific marker of infection and/or inflammation. The non-specific nature lessens the clinical utility as determination of UTIs does not help the care giver to know the type or site of infection and makes it difficult to separate conditions for which the patient would need therapy from general ailments. The present invention is directed toward making such distinctions.

One method of measuring the UTI content of a urine sample involves the addition to the sample of known amounts of trypsin and then measuring the degree to which the trypsin has been inhibited. Examples of this technique can be found in three published U.S. Patent Applications 2001/0055816 A1, 2002/0004219 A1, and 2003/0125577 A1. In these published applications, a known amount of trypsin on a substrate capable of producing a detectable response is added to a sample of urine. The substrate is cleaved by trypsin to yield detectable byproducts. If trypsin inhibitors are present, the response is diminished since some of the available substrate is not cleaved. Thus, by measuring the amount of the trypsin present and functioning relative to the amount added, the UTI content can be determined. This method detects any inhibitor of trypsin activity and is non-specific for any given trypsin inhibitor excreted into urine. The patent application published in 2001 discloses the use of a polycarboxylic chelating agent to inhibit the interference of calcium in the sample. The patent applications published in 2002 and 2003 concern certain aromatic esters of arginine shown to be useful as substrates for trypsin in the method just described.

Another method which determines directly the amount of UTIs in a urine sample involves the development of antibodies which attach themselves to the urinary trypsin inhibitors and which, by the addition of immunoassay reagents containing the antibody to a sample, produce a response signal. There are various immunoassay methods which could be used to apply antibodies of the invention such as microparticle capture immunoassays (MIC), latex agglutination inhibition (LAI), solid phase chromatographic (IC), radioimmunoassays (RIA), enzyme linked immunosorbent assays (ELISA), enzyme linked assays (EIA), fluorescence linked assays (FIA), luminescence linked assays (LIA), rare earth metals label assays, chemiluminescence assays (CLA) and optical color label assays (OA) such as colored latex particle and colloidal gold. It is also feasible to use electrochemical signal transducers (EST) based on amperometric, impedimetric, and potentiometric detection methods.

In principle, immunoassays can be of either a heterogeneous format requiring a separation step or a homogeneous format without separation and either of a competitive

or a non-competitive nature. For heterogeneous assays, solid phases can be used to separate bound antigen from free antigen and can include plastic wells, tubes, capillaries, membranes, latex particles, and magnetic particles. Antibodies are attached to the solid phases. Antibodies can also be attached or conjugated (labeled) with reagents that
5 directly or indirectly produce detectable responses, other antibodies or other reagents in a variety of fashions. An immunoassay can also employ multiple and different antibodies in a variety of manners such sandwich assays, double label assays, and multiple sandwich assays depending on the detection needs for the material being detected.

In general, the immunoassay reagents undergo changes whereby a signal is
10 generated and the intensity of the signal generated is proportional to the concentration of the analyte measured in the specimen or sample. Immunoassay reagents contain indicator dyes, metals, enzymes, polymers, antibodies, surface active agents, particles, electrochemically reactive ingredients and various other chemicals dried or filled onto carriers. Carriers often used are tubes, cups, capillaries, strips, vials, papers, microfluidic
15 devices, cassettes, membranes or polymers with various sample volume, uptake and transport properties.

It has been found that polyclonal antibodies produced from rabbits inoculated with urinary trypsin inhibitors purified from the urine of patients with kidney disease are useful in measuring the amount of total UTIs in urine samples from both healthy
20 individuals and those with disease. However, the polyclonal antibodies are not able to distinguish the various forms of UTI from each other, in particular from the pro-inhibitors interleukin- α -inhibitor (I- α -I) and pre-interleukin- α -inhibitor (P- α -I). Since all these proteins are readily present in the healthy patients, the cross reactivity of the polyclonal antibody makes it useless for distinguishing diseased patients from healthy
25 patients by using blood specimens. In the case of urine specimens, the high molecular weights of P- α -I and I- α -I make it less likely that they will pass through the kidney, thus the polyclonal antibodies were more effective in spite of their reduced specificity. However due to the non-specific nature of the polyclonal antibodies they have not been found to be more effective than the general enzyme inhibition method previously
30 discussed. The polyclonal antibodies were cross-reactive to all forms of UTI in urine and not specific to any one form and would measure both inhibitory and non-inhibitory UTI.

In Journal of Immunoassay 1991; 12:347-69, Trefz et al disclose the use of a monoclonal antibody produced from mice immunized with high molecular weight (240

kDa). Inter- α -trypsin inhibitor (an inactive pro-inhibitor) in an enzyme-linked immunoassay (ELISA). The results showed that the method was effective to distinguish between healthy individuals and those with disease, since the level of UTIs in the urine of those individuals with disease was higher than those without disease. The authors noted that Inter- α -trypsin inhibitor (ITI) having a molecular weight of about 240 kDa, contained several lower molecular weight peptides, understood to result from disintegration of the ITI. Their monoclonal antibody, IA TI5, was found to recognize three major bands, a 240kDa, a 120 kDa, and a 50 kDa band. In a purified HI-30 preparation their monoclonal antibody detected a protein of about 33 kDa.

10 In their work reported in the Journal of Biological Chemistry, Vol. 275, No. 28, issue of July 14, pp. 21185-21191, 2000, Hirashi Kobayashi et al. compared polyclonal and monoclonal antibodies raised against a purified preparation of UTI that was shown to have molecular weight in the range of about 40-80 kDa in SDS-PAGE and Western blotting. Derivatives were found to have molecular weights of about of 7 kDa, 30 kDa, and 60 kDa.

15 During the cross-reactivity studies of a polyclonal antibody for UTI prepared by Bayer, we were surprised to discover that further breakdown of the inhibitory Bikunin occurs during the acute phase infections in patients leading to the formation of other inhibitory UTIs containing both Kunitz inhibitor domains, but lacking the chondroitin sulfate chain. This UTI, termed Uristatin, has a molecular weight of ~17 kDa. In a paper (Clinical Chemistry Acta (2004) 341, 73-81) reporting tests with a dipstick for detecting urinary trypsin inhibitors, Pugia et al showed that the dipstick reported the presence of two forms for UTIs; Bikunins and Uristatins. They identified the typical molecular weight of Bikunin (30.9 kDa) and three key forms of the Uristatin, designated Uristatin-1 (5.9 kDa), Uristatin-2 (8.5 kDa) and the combination of Uristatin-1 and Uristatin-2 which was termed Uristatin (17.4 kDa). All forms of Uristatin lack the chondroitin sulfate chain, and are very prevalent in patient specimens when analyzed by electrophoresis. All Uristatin forms are inhibitory to the trypsin family of proteases; therefore they contain at one of the two Kunitz inhibitory domains that inhibit the protease active site upon binding. Uristatin-1 contains binding domain 2 and Uristatin-2 contains binding domain 1.

20 25 30 It was further noted that, given the conditions of the patient used for collection, the typical molecular weights of IUTIs could vary considerably. Additional variations of

Bikunin and Uristatin are due to fragmentation of peptide structure, variations in the peptide sequence and variations in carbohydrate sequences attached to the Bikunin and Uristatin. Variations in molecular weight resulting from fragments occur by cleavage of the peptide sequence. A high degree of fragmentation is expected during inflammation as the inhibitors are exposed to the proteases that can cause cleavage. Elongation and fragmentation of the carbohydrate portions was also expected during inflammation as the glycoprotein are metabolized by a number of glycosyl transferases and glycosidases causing a great number of possible variants to the chondroitin sulfate chain attached to Bikunin and to the sugar side chains attached to Uristatin. Additional variations also occur by aggregation of the fragments into dimers or higher oligomers, especially through association and metabolism of the carbohydrate portions. Therefore the functional UTI proteins represent a range of possible proteins around a typical molecular weight.

An additional protein in this suprafamily is the precursor protein (AMBK) that initiates the biosynthesis of the inhibitory and pro-inhibitor forms. This protein is present in the plasma of patients when the genes signal up-regulation to initiate the biosynthesis. The AMBK contains the Bikunin but lacks the heavy chains that inactivate the inhibitory domains and is attached to alpha-1-microglobulin. The detection of this form of the inhibitor is also important in determining the body's response to inflammation and infection.

There remains a need for a method of measuring specific urinary trypsin inhibitors that is able to detect the presence of disease by determining certain characteristic UTIs not found in healthy individuals. The present inventors have developed a method for making such determinations by using certain monoclonal antibodies, as will be described in detail below.

Summary of the Invention

The invention includes certain monoclonal antibodies that are able to attach themselves to inhibitory urinary trypsin inhibitors (UTI) characteristic of disease in humans and that can be detected by standard analytical techniques, including MIC, LAI, IC, ELISA, EIA, RIA, LIA CLA, OA and EST (acronyms defined above) in both heterogeneous and homogeneous assays. These monoclonal antibodies are characterized by their ability to allow direct or indirect measurement of urinary trypsin inhibitors such as Bikunin, Uristatin, Uristatin-1 Uristatin-2 and AMBK in the presence of other

common proteins in urine and serum such as Human Serum Albumin (HSA), Tamm-Horsfall protein (THP), α -1-microglobulin (α -1M), α -1-antichymotrypsin (α -1ACT) and non-inhibitory urinary trypsin inhibitors (pro-inhibitor forms) such as I- α -I and P- α -I.

Direct measurement of a UTI may be obtained by either using antibodies that recognize only that particular UTI. Indirect measurement of a UTI may be made by subtraction using antibodies that recognize UTIs other than the one of interest and antibodies that recognize all or most of the prevalent UTIs. In the examples below, antibodies secreted by hybridoma ATCC 421-3G5.4C5.3B6 and hybridoma ATCC 421-5G8.1A8.5C1 are shown to be suitable for determining the amount of UTIs in both urine and blood while hybridoma ATCC 420-5D11.5G8.1E4 is suitable for correction of cross reactivity and determining the amount of UTIs. Other antibodies will be shown to have similar characteristics.

Such monoclonal antibodies may be made by introducing purified UTIs into mice as an immunogen. Single hybridoma clones producing only one antibody have been created by carrying out the procedure of Kohler and Milstein. The characteristic properties of the monoclonal antibodies have been studied, using the Surface Enhanced Laser Desorption/Ionization (SELDI) technique, ELISA, and other immunoassay methods.

In another aspect, the invention includes methods of using the novel monoclonal antibodies to detect and measure forms of urinary trypsin inhibitors of interest, that is, those characterizing persons having disease. Where a monoclonal antibody is specific to an inhibitory UTI, e.g. to Bikunin, and Uristatin, or to the precursor AMBK, they can be measured directly. When a monoclonal antibody is able to bind to more than one UTI, then by using more than one antibody, the content of a particular UTI of interest may be determined by difference. The three monoclonal antibodies referred to above have been found to bind preferentially to Uristatin and Uristatin-1 and -2 (Mab 421-5G8), to the Tamm-Horsfall protein (THP) (Mab 420-5D11), and to all UTIs and THP, but not to the pro-inhibitors (421-3G5).

Analyses may be carried out on samples of many biological fluids, including but not limited to blood, urine, water, saliva, spinal fluid, intestinal fluid, food, and blood plasma. Blood and urine are of particular interest.

Brief Description of the Drawings

Fig. 1 is a bar chart of the results of Example 5.

Fig. 2 is a second bar chart of the results of Example 5.

Fig. 3 is a bar chart of the results of Example 6.

Description of the Preferred Embodiments

Definitions

5 Since the literature has employed various names for enzyme inhibitors, the following will provide definitions for the terms as used herein. It has been found that many variants have been detected in the SELDI analysis discussed below. Consequently, it is believed that the definitions should encompass, not only the principal molecular weight of these inhibitors, but also a range of related molecular weight
10 proteins.

Urinary Trypsin Inhibitors (UTIs) means all the inhibitors identified as inhibiting the serine proteases, including without limitation Bikunin, HI-30, AMBK, Uristatin, Uristatin-1, and Uristatin-2 including fragments and variants and aggregates that are capable of inhibition.

15 HI-30 means a fragment of higher molecular weight urinary trypsin inhibitors that may or may not be identical to bikunin and aggregates. Its monomer molecular weight is reported to be 30 kDa with a range of 21 to 46 kDa for fragments and variants.

20 AMBK means the protein precursor of pro-inhibitors which has three connected proteins namely the inhibitor portion (HI-30) plus alpha-1-microglobulin plus a 25kDa unidentified protein and has a molecular weight of about 66 kDa with chondroitin sulfate and 42 kDa without chondroitin sulfate, in range of 42 to 70 kDa. It is considered to be within the definition of UTI for purposes of the invention, without regard to its function in the biosynthesis of inhibitory serine proteases.

25 Tamm-Horsfall glycoprotein means the glycoprotein also known as uromucoid commonly found in urine and having a typical molecular weight of about 85 kDa with a range of 80 to 91 kDa and including the various fragments and variants of.

Bikunin means a protein consisting of one or two proteinase inhibitor domains of the Kunitz type that can be connected by a short peptide chain and extended by N- and C- terminated polypeptide chains. The protein is linked to a sulphated chondroitin chain and to an oligosaccharide and has a molecular weight of about 33 kDa (range of 21-46
30 kDa). The structure is shown by Pugia et al in Clinical Biochemistry 32 (2002) 105-110 and the 2000 paper by Fries and Blom in the International Journal of Biochemistry & Cell Biology discussed above. The calculated molecular weight of Bikunin is 30.9 kDa

in the presence of both the chondroitin sulfate chain (13.5 kDa) and the sugar side chains (1.9 kDa); these values are based on previously published sequences for HI-30.

Uristatin means a protein fragment of Bikunin resulting from cleaving the chondroitin sulfate chain from Bikunin and having a monomeric molecular weight of about 17 kDa with a range of 11 to 22 kDa for fragments and variants. The calculated
5 molecular weight of Uristatin is 17.4 kDa lacking the chondroitin sulfate chain (13.5 kDa); these values are based on previously published sequences for HI-30.

Uristatin-1 and -2 mean protein fragments of Uristatin which contain either of the Kunitz type inhibitor domains 1 or 2 and have a monomer molecular weight of about 6
10 kDa with a range of 2 to 9 kDa for fragments and variants and about 8.5 kDa with a range of 2 to 12 kDa for fragments and variants respectively. The calculated molecular weight of Uristatin-1 and -2 are 5.9 kDa and 8.5 kDa respectively; the values are based on previously published sequences for HI-30.

Pro-inhibitors mean the non-inhibiting form of the protein precursor of Urinary
15 trypsin inhibitors, including without limitation such as proteins such as I- α -I and p- α -I. These forms are considered inactive UTIs as their measured inhibitory activity is several fold less than Bikunin and Uristatin forms. They are present in healthy and infected patients.

I- α -I means Inter- α -inhibitor, understood to refer to Bikunin attached to two
20 heavy chains, typically H₁ and H₂, by means of the chondroitin sulfate chain with a typical molecular weight of 180-240 kDa. P- α -I means Pre- α -inhibitor, understood to refer to Bikunin attached to one heavy chain, typically H₃ with a typical molecular weight of 125 kDa. The inter-alpha-inhibitor and pre-alpha-inhibitor group are distinct assemblies of Bikunin with heavy chains from a distinct set of four or more heavy (H)
25 chains designated H1, H2, H3, H4, and etc. These H chains are encoded by a set of evolutionarily related H genes, and bikunin is encoded by an alpha-1-microglobulin/Bikunin precursor gene (AMBK).

Monoclonal Antibodies

30 Monoclonal antibodies are distinguished from polyclonal antibodies in being identical and capable of attaching themselves to a single epitope of an antigen. Polyclonal antibodies, in contrast, are not identical and therefore are not able to provide the precise analysis for which monoclonal antibodies are valuable. Monoclonal

antibodies may be produced by the method of Kohler and Milstein, Nature 256:495 (1975). An immunogen (antigen) of interest is injected into mice and the B-cell lymphocytes produced in response to the immunogen are harvested after a period of time. The B-cells are combined with myeloma cells obtained from mice and introduced
5 into a medium which permits the B-cells to fuse with the myeloma cells, producing hybridomas. These fused cells (hybridomas) are then placed in separate wells in microtiter plates and grown to produce monoclonal antibodies. The monoclonal antibodies are tested to determine which of them are suitable for detecting the antigen of interest. After being selected, the monoclonal antibodies can be grown in cell cultures or
10 by injecting the hybridomas into mice.

Making and Separating Preferred Monoclonal Antibodies

Mice are injected with purified UTIs as the analytical target. Antibody producing cells are taken from the animals. Antibody-producing cells are fused with cells that grow
15 continuously in culture to form hybridomas. A single hybridoma produces only one antibody. A single hybridoma divides to produce a large population of 'clones' all making the same "Monoclonal" antibody. Living hybridomas are frozen indefinitely in liquid nitrogen.

The particular procedures used by the present inventors to prepare monoclonal
20 antibodies are described in detail in the examples. It will be understood by those skilled in the art that those procedures can be modified or augmented and that they are not to be considered to limit the scope of the invention. For example, other techniques for both immunization and fusion protocols which yield hybridomas are familiar to workers in the field of monoclonal antibodies.

25 The present invention involves monoclonal antibodies that were selected on the basis of their ability to bind to one or more UTIs and also preferentially to bind to certain epitopes on the intact molecule which then appear on particular fragments once the break-down of the UTIs occurs.

30 Detecting Trypsin Inhibitors in Biological Fluids, e.g. Urine

Once the selective monoclonal antibodies have been located, they may be grown by conventional procedures and used in ELISA testing, or any other immunoassay technique described earlier to detect the presence of UTIs that are characteristic of infection and/or inflammation.

ELISA (enzyme-linked immunosorbent assay) provides a very sensitive method for detecting antigens. In an antigen down ELISA, a microtiter plate receives a sample suspected of containing a certain antigen. After allowing for adsorption of the antigen onto the plate, and washing off all non-bound materials, the monoclonal antibody is
5 added, incubated so that it can bind to the antigen and the excess washed off. The added monoclonal antibody may have already been labeled with a reporter molecule to permit the generation of a signal to be read by any number of techniques. Alternatively a ligand capable of attaching to the antibody (e.g. an anti-mouse antibody conjugated to a reporter molecule) is added. After excess of the enzyme-coupled ligand has been washed off, the
10 chromogen or other substrate is added if necessary and the color developed used as an indicator of the amount of antigen present.

There are various immunoassay methods that could be used to apply antibodies of the invention such as microparticle capture immunoassays (MIC), latex agglutination inhibition (LAI), solid phase chromatographic (IC), radioimmunoassays (RIA), enzyme
15 linked immunosorbent assays (ELISA), enzyme linked assays (EIA), fluorescence linked assays (FIA), luminescence linked assays (LIA), rare earth metals label assays, chemiluminescence assays (CLA) and optical color label assays (OA) such as colored latex particle and colloidal gold. It is also feasible to use electrochemical signal transducers (EST) based on amperometric, impedimetric, and potentiometric detection
20 methods.

Example 1

Preparation of Monoclonal Antibodies

BALB/c mice were immunized with 100 µg/mouse of purified UTIs obtained
25 from renal patients by SciPac Ltd. Sittingbourne, Kent, UK, product code P250-1 to produce a response. The immunogen composition as determined by SDS-PAGE was 15-20% 17 kDa, 50-55% 35 kDa, and 25-30% 60-80 kDa with some material in the 2 to 12 kDa range. After one month, ocular bleeds were taken from each mouse and titered by ELISA against the immunogen to assess the immune response. The mice showing the
30 best response were boosted by injection of 100 µg/mouse with the immunogen. After four days, mice were sacrificed and their spleens used for fusion according to the method of Kohler and Milstein, Nature 256:495 (1975). The spleenocytes were fused with SP2-0 Ag14 myeloma cells using PEG (polyethylene glycol) solution with a ratio of spleenocytes to Myeloma cells of 5:1 and plated into 96 well plates using 50%

PEG/HAT growth media. After 7-10 days of incubation at 37 degrees Celsius, fusion cultures were monitored for growth by feeding every 3-4 days utilizing the HAT (hypoxanthine, aminopterin, thymidine) selection method followed by subculturing with HAT growth media.

5 After 2-3 weeks, the wells having hybridoma colony growth were tested by ELISA to determine which growths produced an antibody immune response to the uristatin peptide. The 96 well plate cultures were tested with the uristatin peptide at 1ug/mL coated plates. After coating plates overnight at 2-8°C, all plates were washed and blocked. Cell culture supernatants were then applied 100µl/well for one hour at
10 room temperature. After washing plates, Goat anti-mouse IgG Horse Radish Peroxidase at 1:2000 dilution was applied at 100uL/well for one hour. Plates were washed once again followed by OPD (o-phenylene diamine dihydrochloride) substrate and read at 490nm on a Spectra Max plate reader.

The colonies giving a positive response were transferred to 24 well plates for
15 further expansion and retesting to verify the positive results. The colonies testing positive were further expanded in six well plates in Iscove's Modified Dulbecco's Medium (IMDM) with 10% Fetal Bovine Serum (FBS). After expansion, the colonies were frozen at - 70°C and then transferred to liquid nitrogen for long-term storage.

Based on ELISA results using the purified UTIs, various clones were further
20 expanded in IMDM, 10% FBS and frozen down.

Example 2

Screening Procedure of Polyclonal Antibodies

25 Rabbit polyclonal antibodies raised against the purified UTIs were used in the screening process as this antibody was expected to be non-specific for any given form of UTIs. Serum and urine specimens from three patients with infection and two healthy controls were characterized by western blot tests using these polyclonal antibodies. The western blot tests used the commercial pre-cast gel system (Invitrogen, San Diego CA).
30 Urine and plasma specimens were loaded with 1 µg and 5 µL per lane. The western blots were stained with a WesternBreeze® chromogenic immunodetection kit (from Invitrogen) following the manufacturer's instructions. Rabbit anti-UTI antiserum was used at a dilution of 1:250 000 as the primary antibody in the western blot analysis (See Table 1). These western blot results demonstrated that the rabbit polyclonal antiserum

body detected Uristatin, Bikunin, AMBK, THP, P- α -I, and I- α -I. The THP cross reactivity was unexpected and likely due to a common peptide sequence between the urinary trypsin inhibitors and THP.

5 Table 1. Results of western blot analysis using polyclonal serum as interrogating antibody of specimens

Specimen	Major proteins observed in urine	Minor proteins observed in urine	Major proteins observed in plasma	Minor proteins observed in plasma
Patient 1	Uristatin	Bikunin, AMBK, THP	P- α -I, I- α -I,	AMBK, Bikunin
Patient 2	Bikunin	Uristatin, AMBK, THP	P- α -I,	AMBK, Bikunin
Patient 3	Bikunin	Uristatin, AMBK, THP	P- α -I,	I- α -I, AMBK, Bikunin
Healthily control 1	None	THP	P- α -I,	I- α -I, AMBK
Healthily control 2	Bikunin	THP, P- α -I, I- α -I, AMBK and THP	P- α -I, I- α -I,	AMBK, Bikunin

10 These western blot tests also demonstrated that Uristatin was better able to differentiate diseased patients from healthy controls than Bikunin, P- α -I, I- α -I, AMBK and THP. All patients and controls had THP in the urine. Similarly all had P- α -I, I- α -I, and AMBK in the plasma. The results showed that Bikunin was found in the urine of the three patients with infections but also in the urine of one control subject. We found
 15 Uristatin in all three patients but not any of the control subjects. Also we found marked increase of Uristatin in one patient. The results showed that AMBK was found in the urine of the three patients with infections but also in the urine of one control subject. This supports our belief that specific forms of UTIs can be more related to disease in certain patients than others. It should be noted here that Bikunin and especially Uristatin
 20 are in much lower concentration in blood than the pro-inhibitors I- α -I and P- α -I because

they pass readily into the kidneys. The pro-inhibitors do not pass through the kidneys into urine in significant amounts, making it easier to detect Uristatin and Bikunin in urine than in blood. THP is excreted in the proximal tubules of the kidney, therefore not required to pass through the kidney, and is the most common protein in the urine as evidenced by presence in patients and controls tested. The high cross reactivity of the polyclonal method does not allow detection of the lower concentrations of Bikunin or Uristatin in blood or urine.

The presence of urinary trypsin inhibitors has been shown to be meaningful in a number of diseases. These diseases include infection (pneumonia, urinary tract infection, upper respiratory tract infection, neonatal sepsis, meningitis, appendicitis, bacterial infections, bone and joint infections), acute inflammation (trauma, kidney stones, surgical trauma, cardiopulmonary bypass, myocardial infarction, and burns), chronic inflammation (rheumatoid arthritis, lung emphysema, inflammatory bowel disease, pancreatitis, Crohn's disease, and as a risk factor for cardiovascular disease), neoplasia (leukemia, multiple myeloma, non-hodgkins lymphoma, ovarian cancer, breast cancer, pancreatic cancer, stomach cancer, colon cancer), and kidney disease.

Clinical value is assessed by the ability of a method to detect the urinary trypsin inhibitor forms more prevalent in disease. Also methods able to work not only in urine but also in blood would be of additional clinical value. Blood is the preferred fluid for clinical laboratory analysis allowing consistency in results, while urine is the preferred fluid for allowing non-invasive sampling at the point of care.

Therefore, an immunoassay which detects only specific forms of UTI's, such as Uristatin, Bikunin, and AMBK but not P- α -I, I- α -I or THP would have clinical utility. The results of our tests also showed that no detectable P- α -I or I- α -I was in urine but was present in all plasma specimens from controls and patients. Any immunoassay of blood for active UTIs such as Uristatin, Bikunin and AMBK should not detect P- α -I or I- α -I. The predominant bands in blood corresponded approximately to an AMBK of 63 kDa, P- α -I of 115 to 125 kDa, and I- α -I of 220 kDa in both patients and controls.

All the monoclonal antibody clones were screened based on their ability to bind UTIs in the ELISA assay using the procedure described in Example 1 and the patterns observed in western blot tests for antibodies using patient and healthy specimens as described in Table 1. The antibodies were grouped by similarity of patterns into three groups and the best representative antibodies of each group selected based on ELISA testing against the UTIs standard. The selection of clones for further study were as

follows, from group A: 421 - 3G5, from group B: 421 - 5G8, and from group C: 420 – 5D11. For the selected mother colonies, cell culture supernatants were cloned out twice using the limiting dilution method assure that the antibodies were monoclonal. The hybridomas secreting these monoclonal antibodies in Iscove's Modified Dulbecco's
5 Medium (IMDM) 30% Fetal Bovine Serum (FBS), and 10% Dimethyl Sulfoxide (DMSO) have been deposited at the American Type Culture Collection and designated as ATCC 420-5D11.5G8.1E4, ATCC 421-3G5.4C5.3B6, and ATCC 420-5G8.1A8.5C1.

Example 3

10

Characterization of Monoclonal Antibodies Against Purified Uristatin and Bikunin Standards

The urinary trypsin inhibitors were produced by SciPac Ltd for our study (Sittingbourne, Kent, UK, product code P205-1); these are purified from the urine of
15 patients with chronic renal failure. The standards were characterized by SDS-PAGE. We used a commercial pre-cast gel system (Invitrogen, San Diego CA) 4-12% NuPAGE® Bis-Tris with a MES (2-morpholinoethanesulfonic acid) running buffers (reducing and non-reducing), following exactly the manufacturer's procedure. Specimens were loaded at 2 µg per lane. Estimations of the proteins' molecular weights were based on a full set
20 of standards: MagicMark12™ (Invitrogen) and SeeBlue®Plus2 (Invitrogen). Protein bands were stained with Colloidal Blue® (Invitrogen).

The results of these tests showed that UTI lot 20-120 contained 15-20% 17kDa proteins, 50-55% 35 kDa proteins, and 25-30% 60-80 kDa proteins. UTI lot 124-111 had about 85% of the material as the 17.4 kDa band (Uristatin) but also contained
25 amounts of Uristatin-1 (5.9 kDa) and 10-15% of Bikunin (30.9 kDa) but no AMBK was seen. UTI lot 80-117 contained substantially only 17 kDa Uristatin material.

These initial results were further refined by the SELDI technique discussed below. It was found that UTI lot 20-120 contained 10 % of 2-12 kDa proteins (Uristatin 1 & 2), 15% of 17 kDa proteins (Uristatins), 45% of 35 kDa proteins (Bikunin), and 30%
30 of 60-80 kDa (AMBK or THP) proteins. UTI lot 124-111 had about 80% of the material as the 17.4 kDa band (Uristatin) but also contained amounts (10%) of Uristatin-1 and 2 (5.9 kDa) and 10% of Bikunin (30.9 kDa) but no AMBK was seen to be present. UTI lot 80-117 containing substantially only the 17 kDa Uristatin material and less than 2 % of other molecular weight ranges.

The urine samples for the controls were assayed by the ELISA assay described in Example 1 using the three monoclonal antibodies selected in Example 2 and a Goat Anti-Mouse secondary antibody conjugate. The results for group A clone 421 – 3G5, group B clone 421 – 5G8 and group C clone 420 – 5D11 are shown in Table 2 and compared to the polyclonal antibody as a control.

The measurements made of color developed by the OPD substrate indicated the amount of the monoclonal antibody bound to UTIs in the standards just described, whose contents were determined by molecular weights using the western blot method and SELDI. The values were normalized using the polyclonal antibody values and are presented in the table below as percent relative to the polyclonal antibody results.

Table 2. ELISA Results with Specimens from Patient and Healthy Individual and Protein Standards for UTIs.

Specimen	2-12/17/35/ 60-80 kDa %	ANTIBODY GROUP B CLONE 421 - 5G8	ANTIBODY GROUP C CLONE 420 – 5D11	ANTIBODY GROUP A CLONE 421 – 3G5	POLYCLONAL ANTIBODY
UTI Standard lot 20-120	10/15/45/30	92%	100%	71%	100%
UTI Standard lot 124-111	10/80/10/0	100%	13%	100%	94%
UTI Standard lot 80-117	0/100/0/0	5%	0%	48%	74%

The monoclonal antibody 421-5G8 bound strongly to UTI lots #124-111 and #20-120 to a similar degree, but only bound weakly to Lot #80-117. This would be consistent with binding to the 2-12 kDa material (Uristatin 1 or 2) in both lots but not in lot 80-117 containing only the 17 kDa material (Uristatin). Thus, this antibody appears specific for Uristatin 1 or 2 over Bikunin and Uristatin. While not wanting to be limited to a mechanism, it is believed that binding by this monoclonal antibody does not occur through the sulfated chondroitin chain as these moieties are known to possess high antigen affinities for antibodies. The binding is thought to be direct to an inhibitory amino acid sequence.

The monoclonal antibody 420-5D11 bound strongly to UTI lot #20-120, very weakly to lot #124-111, and did not bind to lot 80-117. This is consistent with binding to

the 80 kDa material (THP) in lot #20-120, since only lot #20-120 contains a large amount of this material. If the antibody were specific for Uristatin or Bikunin also, one would expect it to have strongly responded to lot #124-111, which contained about 65% of Uristatin. This antibody appears to bind to THP but also to Bikunin and Uristatin.

5 While not wanting to be limited to a mechanism, it is believed that binding by this monoclonal antibody does not occur through a common amino acid region between THP and Bikunin or Uristatin. Sequence matching has shown enough homology in the Uristatin 1 and 2 domains for this to be possible.

The monoclonal antibody 421 – 3G5 bound strongly to all UTI lots and similar to
10 the non-specific polyclonal antibody with the notable exception of lacking reactivity to P- α -I and I- α -I. Thus 421-3G5 would be a measure of total UTI.

Example 4

Testing of Monoclonal Antibodies with Clinical Specimens

15 Urine samples were obtained from patients having bacterial infections and from control patients having no such infections. The patients without infections are the “group 1” patients. To be included in the study, we only required a negative urine and blood culture (10^5 organisms/mL) and a normal blood white blood count (CBC). The second group of patients (“group 2”) included those with infections either upper
20 respiratory tract or urinary tract, a conclusion based on a positive complete blood count (CBC) in all. Clean-catch midstream urine collections were obtained from all patients and controls. Specimens were stored at 4°C until tested; but if not tested within 24 hours, storage was at –70 °C until tested. For all subjects, the evaluation of urine sediment, gram stain and urine microbiological culture were always performed on the
25 day of collection. We collected EDTA-anticoagulated blood from group 2 and performed a CBC, a high sensitivity CRP (Dade Behring, Immunoassay for C-reactive protein) test, and a blood culture and performed all these tests on the day of blood collection.

The urine samples were also assayed by an ELISA assay using the same
30 polyclonal antibodies as in Example 2. The antibodies were immobilized in polystyrene membrane wells of the high binding microtiter plates (PN 3690 Corning Life Sciences, Acton, MA), then wells were coated with Super Block (Pierce Chem Co., Rockford IL) to ensure none of the following additions attach directly to the plate, then contacted with

a urine sample from each patient to bind the antibodies to the UTIs in the sample. The UTI-antibody complex was reacted with a second antibody (goat anti-rabbit antibody) conjugated to alkaline phosphatase, then the unbound conjugated antibody was washed away with TBS/2 % TWEEN-20 (ELISA Wash buffer, Upstate Cell Signaling Solutions, Lake Placid NY) and the immobilized antibody assayed by determining the alkaline phosphatase on the plate by hydrolysis of PNPP (*p*-Nitrophenyl Phosphate, Disodium Salt) forming an absorbance at 405 nm (yellow) color upon addition of Diethanolamine Buffer (Pierce Chem Co.). The absorbance was measured a spectrophotometric micro titer-plate reader (SpectroMax. Molecular Devices Corporation, Sunnyvale, CA).

It was found that three control urine samples contained 51.4, 27.9 and 24.8 $\mu\text{g/mL}$ of UTI proteins (Bikunin, Uristatin, and AMBK), while two samples from patients having bacterial infections contained 148 and 49.5 $\mu\text{g/mL}$. This result confirms the previous western blot test findings that polyclonal antibody gave poor separation of patients with infections from healthy controls as would be expected by the cross-reactivity between P- α -I, I- α -I and THP proteins and the desired measured proteins Bikunin, Uristatin, and AMBK.

Measurements of UTI's in the urine and plasma of patients can be made specific by the direct method and the indirect subtraction method using monoclonal antibodies, such as those shown in Table 2. As an example of direct method, Uristatin 1 or 2 in either a urine or blood specimen can be measured directly with clone 421 - 5G8 over the other UTI, THP and pro-inhibitors present. An additional example of direct method, all of the UTIs (IUTI) in either a urine or blood specimen can be measured directly with clone 421 - 3G5, but not the pro-inhibitors. An example of indirect method would be subtraction of one or more specific results from a total measurement of UTI. For example, to measure the Bikunin in patient 1's urine, Uristatin 1 or 2 would be measured directly with clone 421 - 5G8 and would be subtracted from a total IUTI 421 - 3G5 to arrive at the amount Bikunin and AMBK. Additionally any cross-reactivity to THP can be measured directly with clone 420 - 5D11 and could be subtracted from an UTI antibody with cross reactivity to THP, such as the polyclonal antibodies, to arrive at the amount of UTI. A total measurement could be made by the polyclonal antibody as discussed above, monoclonal antibody clone 421 - 3G5 or the enzyme inhibition method. In the case of the polyclonal antibody, it was shown that this total was affected by the pro-inhibitor amounts, therefore the monoclonal antibody clone 421 - 3G5 or enzyme

inhibition method would be preferred or a correction by subtraction of a pro-inhibitor result could be used.

Example 5

5 In Example 3, three monoclonal antibodies were tested for their response to three lots of purified UTIs. This example reports the same monoclonal antibodies, along with an additional sixteen monoclonal antibodies. The results are shown in Figs. 1&2, a series of bar graphs.

The same three lots of purified UTIs were used. UTI lot 20-120 contained 10 %
10 of 2-12 kDa proteins (Uristatin 1 & 2), 15% of 17 kDa proteins (Uristatins), 45% of 35 kDa proteins (bikunin), and 30% of 60-80 kDa (AMBK or THP) proteins. UTI lot 124-111 had about 80% of the material as the 17.4 kDa band (Uristatin) but also contained amounts (10%) of Uristatin-1 and 2 (5.9 kDa) and 10% of Bikunin (30.9 kDa) but no AMBK was seen to be present. UTI lot 80-117 containing substantially only the 17 kDa
15 Uristatin material and < 2 % of other molecular weight ranges.

It can be seen that the lot containing substantially only 17 kDa material was generally bound less strongly than those lots that contained low and high molecular weight species. However, additional monoclonal antibodies were found to bind all three lots in a manner similar to that of the polyclonal antibody control (for example 421-
20 1D11, 421-5B9, and 421-2D5) and would be expected to be similar to 421-3G5. Several antibodies were found to bind the three lots similarly to 421-5G8, for example 421-1C10, 421-1C12, 421-2A11, and 421-2G4. The notable exception was again confirmed with monoclonal antibody 420-5 D11, which showed an affinity for lot 20-120, but not for lots 124-111 and 80-117. It can be concluded that monoclonal antibody 420-5 D11 did
25 not bind strongly to the lower molecular weight uristatin (17 kDa) and bikunin (35 kDa) but preferred the higher molecular weight material (60-80 kDa THP and AMBK are in this range). 420- 5D11 was the only monoclonal antibody from the fusion designated 420 (the others were derived from fusion 421). Its distinctive behavior suggested further testing of monoclonal antibodies, which is reported in Example 6.

30

Example 6

Nine monoclonal antibodies from fusion 420 were tested in addition to 420-5D11. Five lots of UTI's were used. Lots 20-120, 124-111, and 80-117 were included again and lots 93-90 (similar to 124-111) and 157-90 (similar to 20-120) were added.

The results shown in Fig. 3 show that monoclonal antibody 420-5D11 was similar to 420-1B7, 420-1G4, and 420-4E11, binding mainly to lots that contained a significant amount of higher molecular weight material, i.e. 60-80 kDa found in lots 20-120 and 157-90. The other monoclonal antibodies showed substantially no binding of the UTIs.

5 The control used in these experiments was a monoclonal antibody from fusion 421 (421-5B9) that had been found to have a binding profile similar to the polyclonal antibodies but without pro-inhibitor binding, that is, the monoclonal antibody of 421-5B9 binds to each of the UTI lots strongly.

Example 7

10

Two samples of purified total UTIs used in the previous ELISA tests and two samples from patients were reacted with the three representative monoclonal antibodies and one polyclonal antibody and analyzed to determine the proteins binding to the antibodies, using Surface Enhanced Laser Desorption/Ionization (SELDI) technology (15 PBS II SELDI mass spectrometer from Ciphergen, Fremont, California. Binding was measured on two types of surfaces using a standard incubation procedure (High Binding PS20 Chip and a low binding RS100 Chip). The signal to noise (S/N) was determined for each mass bound to the antibody as a measure of significance.

Also analyzed by mass spectroscopy were two urine samples from patient 4 and 20 patient 5 reacted with antibodies. Both patients were affected by inflammation with elevated white blood cells (by complete blood cell count), C-reactive protein (by high sensitivity immunoassay), ESR(erythrocyte sedimentation rate), urinalysis (by ten panel MULTISTIX PRO dip strip) and total urinary trypsin inhibitors (by inhibitor assays). Patient 5 was positive for a blood bacterial infection (toxemia) and patient 4 was positive 25 for a urinary bacterial infection (Urinary tract infection) both by microbiological cultures.

The procedure followed is outlined as follows:

1. Three μL of 50 mM NaHCO_3 (pH 8.0) was added to each spot on the protein chip, which was covered by a plate to form sample wells.
- 30 2. One μL of 1mg/mL of the antibody was added to each spot and incubated at room temperature for 2 hours with shaking in a humidity chamber.

3. The solution was removed from each spot and the spot was washed twice with 5 μ L of washing buffer, phosphate buffered saline (PBS + 0.5% Triton detergent).
4. The unbound sites were blocked with 5 μ L or 2mg/mL BSA (bovine serum albumin) or 1 M ethanolamine.
5. After incubation at room temperature, the BSA or ethanolamine were discarded.
6. The spots were twice washed with 5 μ L of washing buffer (PBS + 0.5% Triton).
7. Five μ L of PBS was added to each spot and the chips were placed in a bioprocessor. An additional 10 μ L of PBS was added in each well.
8. Ten μ L of the sample to be tested (or PBS as a control) was added to each well, then the wells were sealed and shaken at 4°C overnight.
9. The wells were washed twice with washing buffer and PBS and then shaken at room temperature for 2 minutes.
10. The wells were rinsed twice with 300 μ L of deionized water saturated with sinapinic acid.
11. The chips containing the antibodies and samples were analyzed by surface enhanced laser desorption/ionization (SELDI).

The SELDI results for the four antibodies are reported in the Table 3 and 4. The results are the masses of proteins bound to the antibodies after exposure to the UTIs in the patients and purified samples. The high sensitivity of this method demonstrates antibody binding to a great many more forms than were detected by the ELISA method. The abundance of forms is expected from the fragmentation, elongation and aggregation that is responsible for the molecular weight ranges for the functional classes of UTI. This method identified exactly the forms bound and does not rely on any interpretation by the composition of the standard. Therefore even though protein bound might be a small percentage of the composition, it will be detected if there is binding to the antibody. Antibody binding epitopes are typically small, on the order of 2 to 5 kDa,

when antibodies bind to the peptide or glycoprotein sequence in favor of the tertiary structure of the protein sequences. Therefore a common sequence would be expected to be repeated in all variations and the ability of SELDI to detected all binding events allows a great many variations to be demonstrated. Results from all samples are combined and organized by functional protein groups according to the observed molecular weight falling with ranges for Uristatin 1 or 2, Uristatin, Bikunin, AMBK, THP and the pro-inhibitors. Those binding events of high affinity, frequency or importance are in bold face as determined by signal-to-noise ratios of binding events. The primary binding events are in bold face and underlined. Weak binding events are in plain text to document variations in the proteins. These represent very weak cross-reactivities of the type that would not impact an immuno-assay if properly formatted.

Table 3. SELDI Results Comparison of Three Novel Monoclonal Antibodies for UTIs versus a Standard Polyclonal Antibody for a total measurement of all UTI and pro-inhibitors using purified UTI standards.

IUTI Functional Group	Mab 421-3G5	Mab 421-5G8	Mab 420-5D11	polyclonal Rb Anti-Uristatin
	IUTI clone	Uristatin clone	THP clone	IUTI and Pro-UTI
Uristatin 1 or 2 -(average molecular weights of 5.9 & 8.5 kDa with kDa range 2-12)	3.48, <u>3.86</u>	<u>3.48</u> , <u>3.86</u>	<u>3.48</u> , <u>3.86</u>	3.49, <u>3.86</u>
Uristatin (17 kDa, range 11-22)	15.9, <u>17.8</u> , 16.3, 18.0	<u>15.9</u> , 18.3	<u>15.9</u> , 16.3 <u>18.2</u>	15.9, <u>17.8</u>
Bikunin (33 kDa, range 21-46)	No significant peaks	No significant peaks	41.5, 48.1	<u>42.5</u> , <u>42.6</u>
AMBK (66 kDa, range 42-70)	<u>62.9</u> , 62.5,	No significant peaks	67.1	<u>66.6</u> , <u>66.7</u>
THP (85 kDa, 80-91 kDa)	81.9	81.7	<u>81.7</u>	<u>82.6</u>
p-alpha-I (125 kDa)	No significant peaks	122.6	No significant peaks	<u>108.6</u> , 120.0, 142.7
I-alpha-I (220 kDa)	No significant peaks	No significant peaks	No significant peaks	No significant peaks

Table 4. SELDI Results Comparison of Three Novel Monoclonal Antibodies for UTIs versus a Standard Polyclonal Antibody for a total measurement of all UTI and pro-inhibitors using purified patient samples.

IUTI Functional Group	Mab 421-3G5	Mab 421-5G8	Mab 420-5D11	polyclonal Rb Anti-Uristatin
	IUTI clone	Uristatin clone	THP clone	IUTI and Pro-UTI
Uristatin 1 or 2 - (average molecular weights of 5.9 & 8.5 kDa with kDa range 2-12)	2.82, 3.41, 3.48, 5.38, 5.57, 6.30, 7.24, 3.5, 3.8, 4.0, 5.6, 6.0, 6.3, 8.0, 9.2, 9.8, 10.9	2.82, 3.41, 3.48, 4.0, 5.4, 7.2, 9.18, 9.85	2.82, 3.0, 3.5, 4.7, 3.7, 5.4, 5.6, 7.2, 3.7, 10.8	2.8, 5.0, 5.4, 7.2, 10.7, 3.5, 4.0, 5.9, 6.0, 6.3, 8.1, 10.7
Uristatin (17 kDa, range 11-22)	11.8, 18.0, 16.3, 13.4, 14.0	12.0, 14.0, 13.5, 21.1	11.9, 13.5, 21.1,	13.4, 14.0, 16.3
Bikunin (33 kDa, range 21-46)	21.1, 33.6, 35.2, 33.5, 45.9	23.0, 22.7	23.3, 41.6	21.2, 22.6, 23.3, 33.4, 33.1, 35.2, 42.3
AMBK (66 kDa, range 42-70)	67.0	No significant peaks	No significant peaks	58.6
THP (85 kDa, 80-91 kDa)	81.9, 91.1	No significant peaks	80.2, 80.6, 81.9	82.6, 79.2
p-alpha-I (125 kDa)	No significant peaks	128.5, 132.1	No significant peaks	101.1, 103.7, 106.3, 120.0, 123.4, 133.0, 142.7
I-alpha-I (220 kDa)	No significant peaks	No significant peaks	No significant peaks	No significant peaks

5 Mass differences were rounded to nearest 0.1 kDa. Peaks with highest Signal to Noise ratios (S/N) relative to other peaks are reported. Low S/N observations were eliminated from table. The table represents most but not all possible forms. Spectra also showed peaks at 66.9 to 66.6 and 33.3 and 133.0 to 133.9 that were due to albumin used in the blocking procedure for the SELDI analysis. When triethanolamine was used to
10 block chips those peaks were not observed.

The results demonstrated that the three types of monoclonal antibodies detect different patterns of UTIs and these patterns include a range of variants. The monoclonal antibodies are specific for UTIs whereas the polyclonal antibodies detect both UTIs and Pro-inhibitors. We can not see all the urinary trypsin inhibitor fragments that the clones detect in the patterns represented in the SDS gels. The gel method is not sensitive enough to report all of the UTIs the antibody can bind. More of the fragments actually bound are shown in the SELDI data. All fragments bound are not listed as additional variations would be found as different patients are tested. The extent or strength of binding to a given UTI was estimated relative to other UTIs. The strongest binding by smallest fragments are the best representation of the epitopes bound by each antibody. The low molecular weight sequences in the Uristatin 1 or 2 functional groups are the smallest linear sequence with strong binding.

In Tables 3 and 4 using purified standards and patients, the primary binding for Mab 421-3G5 was strong for Uristatin-1 or -2, Uristatin, Bikunin, and AMBK and much less strong for THP with no significant pro-inhibitor binding. The primary binding for Mab 421-5G8 was with Uristatin-1 or -2, less for Uristatin and much less strong for THP or Bikunin or pro-inhibitors. The primary binding for Mab 420-5D11 was strong for THP, Uristatin, and Uristatin-1 or -2, less strong for Bikunin or AMBK. The polyclonal binding was with all forms including the pro-inhibitors. These results were as expected based on SDS gels. The SELDI results however also demonstrated that all three antibodies bound to Uristatin-1 or -2 in the standards very strongly at 3.9, and with high affinity at 2.8 and 3.5. The SELDI results also show several low affinity binding events, not strong enough to hinder specificity, but measurable.

The results in Table 4 using individual patient samples, demonstrate the same primary binding patterns for Mab 421-3G5, Mab 421-5G8, Mab 420-5D11 and the polyclonal shown with the standards. Again these results were as expected based on SDS gels. The SELDI results however also demonstrated that all three antibodies strongly bound to several new forms of Uristatin-1 or -2, Uristatin, Bikunin and AMBK within the expected ranges for each. In particular primary binding to 2.8, 5.4, 7.2, 11.8, 21.1, and 67.0 kDa were observed in patient samples but not in the purified standards. This demonstrated the variations expected in pathological conditions for reasons previously stated. The lack of these peaks in the purified standards is the result of the pooling of many patient and purification of specimens to the target molecular weight

targets of 15, 30 and 60 kDa. The SELDI also showed at least some cross-reactivity to THP in the polyclonal and Mab 420-5D11 case.

Example 7

5 Four proteins, Human Serum Albumin (HSA), Tamm-Horsfall protein (THP), α -1-microglobulin (α -1M), and α -1-antichymotrypsin (α -1ACT) were tested for crossreactivity in the Uristatin sandwich ELISA test. These proteins were chosen either because of their high concentration in urine or because they were suggested as possible cross reactants during the western blot or SELDI work that used these antibodies with
 10 urine samples. Cross reactivity studies were done in a competitive format to allow relative binding to be compared. For example the binding of antibodies to uristatin was significantly stronger than to THP, the assay for uristatin was not interfered with by THP. The only proteins and antibodies found to be cross-reactive in the competitive sandwich ELISA test was THP with Mab 420-5D11 and the polyclonal antibody (See Table 5).

15

Table 5. Cross-reactivity Results Comparison of Three Novel Monoclonal Antibodies for UTIs versus a Standard Polyclonal Antibody using purified protein standards.

<u>Antibody</u>	<u>Crossreactivity Result for Proteins Tested</u>			
	<u>HSA</u>	<u>THP</u>	<u>α-1MG</u>	<u>α-1ACT</u>
<u>Mab 421-3G5</u>	<u>none</u>	<u>none</u>	<u>none</u>	<u>none</u>
<u>Mab 421-5G8</u>	<u>none</u>	<u>none</u>	<u>none</u>	<u>none</u>
<u>Mab 420-5D11</u>	<u>none</u>	<u>=approx. 100%</u>	<u>none</u>	<u>none</u>
<u>Rb-anti-Uristatin</u>	<u>none</u>	<u>>= 50%</u>	<u>none</u>	<u>none</u>

The broad objective of the invention is to provide a method for conveniently
 20 testing the urine of medical patients to identify the presence of diseases by their association with inhibitory urinary trypsin inhibitors (UTI). It has been previously noted that the presence in urine of UTIs indicates disease. Heretofore, it has not been possible to relate particular UTIs with certain diseases since the UTIs generally were measured in the aggregate, rather than individually. The present inventors have developed
 25 monoclonal antibodies using samples of UTIs isolated from the urine of known renal disease patients and associated the monoclonal antibodies with the various fragments of

the non-inhibitor precursors of UTIs. As the examples have shown, the monoclonal antibodies have been found to have varying responses to the samples of UTIs, which enable one to identify their preference for certain of the UTIs. Additional investigation by mass spectroscopy has extended the information available about the composition of the UTI samples and the response of the monoclonal antibodies to them. One important finding has been the discovery that a lower molecular weight UTI fragments, at about 2.8, 3.5, 3.9 and 5.4 kDa was an important component in the total UTIs observed in samples. That result was not seen in SDS-Page testing as only the proteins with the highest concentration are visualized and consequently the results of ELISA testing with the monoclonal antibodies could not be completely interpreted. Since the use of mass spectroscopy in routine clinical work is impractical, the present inventors have applied the information obtained from mass spectroscopy to interpretation of the results of ELISA tests, which may be more readily used in clinical settings.

The proposed procedures for testing urine samples may be outlined as follows:

1. Prepare monoclonal antibodies against known sources of one or more UTIs.
2. Test the monoclonal antibodies against the known sources of UTIs and select those that are found to have a preference for UTIs having known molecular weights.
3. Add the selected monoclonal antibodies to a sample of urine containing unknown amounts of UTIs and determine which UTIs are present and their relative amounts.
4. Correlate the UTIs determined in step 3 with a disease associated with the measured distribution of UTIs.

The UTIs that have been identified by SDS-PAGE methods and correlated with ELISA tests include fragments of the I- α -I and P- α -I non-inhibitors that have typical average molecular weights of about 66 kDa (AMBK), 30 kDa (Bikunin or HI-30), 17 kDa (Uristatin), 5 kDa (Uristatin-1), 8 kDa (Uristatin-2) and ranges defined around these averages due to fragmentation, variation and aggregation. In particular, it was found also that smaller fragments having molecular weights of about 2 to 5 kDa were present. Those were designated as fragments of Uristatin-1 and 2. It now appears from mass spectroscopy that fragments at about 2.8, 3.5, 3.8 and 5.0 kDa are present in samples and bound by antibodies, but not clearly shown by the SDS-PAGE results.

The monoclonal antibodies appeared to be grouped in their response to samples containing known distributions of particular UTIs. That is, some appeared to bind to UTI samples containing significant amounts of 2-12 kDa fragments (Uristatin 1 or 2),

while others appeared to bind to UTI samples containing a large fraction of AMBK, Bikunin or the Uristatin fractions of 62, 30 and 17 kDa. Still others bound to Bikunin, Uristatin fractions and THP common sequence. Three monoclonal antibodies were selected as characteristic of their groups and those antibodies were deposited in the ATCC depository. Other monoclonal antibodies having similar properties are identified and their performance reported in the examples for further information.

The advantage of identifying monoclonal antibodies having a preference for certain UTIs is of course that it opens the possibility of distinguishing certain diseases or other medical problems with a particular distribution of UTI fragments. Certain antibodies may be specific for binding certain UTI fragments or for certain combinations of fragments. Then, by using those monoclonal antibodies in ELISA or other such tests it will be possible to identify which of the UTIs are present and their relative proportions.

WHAT IS CLAIMED IS:

- 2 1. A monoclonal antibody for detecting urinary trypsin inhibitors in the
biological fluids of persons having disease, said antibody comprising an antibody
4 combining site which binds preferentially to at least one member of the group of urinary
trypsin inhibitors (UTI) consisting of AMBK, Bikunin, Uristatin, Uristatin-1, Uristatin-2
6 and fragments and aggregates thereof.
2. A monoclonal antibody of Claim 1 wherein said UTIs are Uristatin and
8 Uristatin-1 and -2.
3. A monoclonal antibody of Claim 1 wherein said monoclonal antibody is
10 secreted by hybridoma ATCC 421-5G8.1A8.5C1.
4. A monoclonal antibody of Claim 1 wherein said UTIs are Uristatin and
12 Uristatin-1 and -2 and said monoclonal antibody further binds to Tamm-Horsfall protein
(THF).
- 14 5. A monoclonal antibody of Claim 4 wherein said monoclonal antibody is
secreted by hybridoma ATCC 420-5D11.5G8.1E4.
- 16 6. A monoclonal antibody of Claim 1, wherein said monoclonal antibody
binds preferentially to the UTIs AMBK, Bikunin, Uristatin, and Uristatin 1 and 2 and
18 also to THP.
7. A monoclonal antibody of Claim 6 wherein said monoclonal antibody is
20 secreted by hybridoma ATCC 421-3G5.4C5.3B6.
8. A monoclonal antibody of Claim 1 for detecting UTI wherein said
22 biological fluid is urine.
9. A monoclonal antibody of Claim 1 for detecting UTI wherein said
24 biological fluid is blood.
10. A method of assaying a biological fluid for urinary trypsin inhibitors
26 (UTI) comprising contacting a sample of biological fluid with at least one monoclonal
antibody capable of binding to urinary trypsin inhibitors characterizing said biological
28 fluid of persons having disease and identifying the bound UTIs.
11. A method of Claim 10 wherein said urinary trypsin inhibitors
30 characterizing the urine of persons having disease are members of the group consisting
of AMBK, Bikunin, Uristatin, Uristatin-1, Uristatin-2, and fragments and aggregates
32 thereof.

12. A method of Claim 11 wherein said monoclonal antibody binds
2 preferentially to the UTIs Uristatin, Uristatin-1 and -2, and also to Tamm-Horsfall
protein (THP).
- 4 13. A method of Claim 12 wherein said monoclonal antibody binds
preferentially to the UTIs Uristatin and Uristatin-1 and -2.
- 6 14. A method of Claim 11 wherein said monoclonal antibody binds to the
UTIs AMBK, Bikunin, Uristatin, and Uristatin-1 and -2 and also to THP.
- 8 15. A method of Claim 12 wherein said monoclonal antibody is secreted by
hybridoma ATCC 420-5D11.5G8.1E4.
- 10 16. A method of Claim 13 wherein said monoclonal antibody is secreted by
hybridoma ATCC 421-5G8.1A8.5C1.
- 12 17. A method of Claim 14 wherein said monoclonal antibody is secreted by
hybridoma ATCC 421-3G5.4C5.3B6.
- 14 18. A method of Claim 10 wherein said UTIs are identified in an
immunoassay.
- 16 19. A method of Claim 18 wherein said immunoassay is selected from the
group consisting of MR, LAI, IC, RIA, ELISA, EIA, FIA, LIA, CLA, OA, and rare earth
18 metals label assays, as defined herein.
20. A method of Claim 10 wherein said biological fluid is urine.
- 20 21. A method of Claim 10 wherein said biological fluid is blood.
22. A method of Claim 10 wherein a UTI is measured directly by a
22 monoclonal antibody.
23. A method of Claim 10 wherein all UTIs are measured by a first
24 monoclonal antibody and specific UTIs measured by a second antibody are subtracted
from the UTIs measured by the first antibody to measure the UTIs found by first
26 antibody but not by the second antibody.
24. A method of Claim 22 wherein said antibody measures Uristatin-1 and/or
28 Uristatin-2.
25. A method of Claim 22 wherein said antibody measures all UTIs but not
30 the pro-inhibitors.
26. A method of Claim 23 wherein said first antibody measures Uristatin-1
32 and/or Uristatin-2 and said second antibody measures all UTIs and Bikunin and AMBK
are measured by difference.

27. A method of Claim 23 wherein said first antibody measures all
2 UTIs and THP and said second antibody measures THP and UTIs are measured by
difference.

4 28. A method of assaying a biological fluid for urinary trypsin inhibitors
(UTI) comprising the steps of:

6 (a) adding a biological fluid sample suspected of containing urinary
trypsin inhibitors to a substrate;

8 (b) adding to said sample of (a) monoclonal antibodies capable of
binding to urinary trypsin inhibitors characterizing the biological fluid of humans having
10 disease;

(c) adding to the combined monoclonal antibodies of (b) and the urine
12 sample of (a) a ligand capable of binding to said monoclonal antibodies, said ligands
being bound to an enzyme;

14 (d) washing from the combined monoclonal antibodies of (b), the
biological fluid sample of (a) and the ligand of (c) the portion of said ligand unbound to
16 said monoclonal antibodies;

(e) determining the amount of said urinary trypsin inhibitors bound to
18 said monoclonal antibodies and said ligands by adding a reporter molecule capable of
developing a signal by reaction with said enzyme and correlating the signal developed
20 with the amount of said urinary trypsin inhibitors.

22 29. A method of Claim 28 wherein said urinary trypsin inhibitors
characterizing the biological fluid of persons having disease comprise at least one
member of the group consisting of AMBK, Bikunin, Uristatin, Uristatin-1, Uristatin-2
24 and fragments and aggregates thereof.

30 30. A method of Claim 29 wherein said monoclonal antibody binds
preferentially to the UTIs Uristatin, Uristatin-1 and -2, and also to Tamm-Horsfall
protein (THP).

28 31. A method of Claim 29 wherein said monoclonal antibody binds
preferentially to Uristatin and Uristatin-1 and -2.

30 32. A method of Claim 29 wherein said monoclonal antibody binds
preferentially to the UTIs AMBK, Bikunin, Uristatin, and Uristatin-1 and -2 and also to
32 THP.

- 2 33. A method of Claim 30 wherein said monoclonal antibody is
secreted by hybridoma ATCC 420-5D11.5G8.1E4.
- 4 34. A method of Claim 31 wherein said monoclonal antibody is secreted by
hybridoma ATCC 420-5G8.1A8.5C1.
- 6 35. A method of Claim 32 wherein said monoclonal antibody is secreted by
hybridoma ATCC 421-3G5.4C5.3B6.
- 8 36. A method of Claim 28 wherein said biological fluid is urine.
37. A method of Claim 28 wherein said biological fluid is blood.
- 10 38. A method of Claim 28 wherein a UTI is measured directly by a
monoclonal antibody.
- 12 39. A method of Claim 28 wherein all UTIs are measured by a first
monoclonal antibody and specific UTIs measured by a second antibody are subtracted
from the UTIs measured by the first antibody to measure to UTIs found by the first
14 antibody but not by the second antibody.
- 16 40. A method of Claim 38 wherein said antibody measures Uristatin-1 and/or
Uristatin-2.
- 18 41. A method of Claim 38 wherein said antibody measures all UTIs but not
the proinhibitors.
- 20 42. A method of Claim 39 wherein said first antibody measures Uristatin-1
and/or Uristatin-2 and said second antibody measures all UTIs and Bikunin and AMBK
are measured by difference.
- 22 43. A method of Claim 39 wherein said first antibody measures all UTIs and
THP and said second antibody measures THP and UTIs are measured by difference.




Fig. 1




Fig. 2




Fig. 3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/024881

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07K16/38 G01N33/53		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K G01N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, WPI Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TREFZ G ET AL: "ESTABLISHMENT OF AN ENZYME-LINKED IMMUNO-SORBENT ASSAY FOR URINARY TRYPSIN INHIBITOR BY USING A MONOCLONAL ANTIBODY" JOURNAL OF IMMUNOASSAY, MARCEL DEKKER, BASEL, CH, vol. 12, no. 3, 1991, pages 347-369, XP009008646 ISSN: 0197-1522 cited in the application page 349, paragraph 3 - page 351, paragraph 1 page 352, paragraph 2 page 355, paragraph 2 - page 360, paragraph 1 ----- -/--	1, 2, 6, 8-11, 14, 18-23, 28-30, 32, 36-39
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		
<input checked="" type="checkbox"/> Patent family members are listed in annex.		
° Special categories of cited documents :		
A document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
E earlier document but published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.	
O document referring to an oral disclosure, use, exhibition or other means	*&* document member of the same patent family	
P document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search <p style="text-align: center; font-weight: bold;">30 March 2005</p>	Date of mailing of the international search report <p style="text-align: center; font-weight: bold;">08/04/2005</p>	
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer <p style="text-align: center; font-weight: bold;">Page, M</p>	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/024881

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>US 6 242 197 B1 (PAPUASHVILI MARINA N) 5 June 2001 (2001-06-05)</p> <p>column 3, line 58 - line 63 column 4, line 59 - line 67 example 1</p>	1,2,6, 8-11,14, 18-23, 28-30, 32,36-39
X	<p>KOBAYASHI HIROSHI ET AL: "Identity of urinary trypsin inhibitor-binding protein to link protein" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 28, 14 July 2000 (2000-07-14), pages 21185-21191, XP002322618 ISSN: 0021-9258 cited in the application Page 21187: RESULTS - Characterization of mAb 8H11table 1</p>	1,2,6,8
X	<p>US 2003/190732 A1 (JOSIC DJURO) 9 October 2003 (2003-10-09) paragraph '0020!</p>	1,6,8,9
A	<p>PUGIA MICHAEL J ET AL: "Clinical utility of a rapid test for uristatin" CLINICAL BIOCHEMISTRY, vol. 35, no. 2, March 2002 (2002-03), pages 105-110, XP002322619 ISSN: 0009-9120 figure 1</p>	1-43

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US2004/024881

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
US 6242197	B1	05-06-2001	DE 19920704 C1	31-08-2000
			AT 271225 T	15-07-2004
			AU 770114 B2	12-02-2004
			AU 2439600 A	18-08-2000
			CA 2361000 A1	03-08-2000
			DE 60012140 D1	19-08-2004
			WO 0045175 A1	03-08-2000
			EP 1147420 A1	24-10-2001
			JP 3534703 B2	07-06-2004
			JP 2002535679 T	22-10-2002
US 2003190732	A1	09-10-2003	AU 1696802 A	22-04-2002
			WO 0230983 A2	18-04-2002
			EP 1326893 A2	16-07-2003
			JP 2004511492 T	15-04-2004

专利名称(译)	用于检测尿胰蛋白酶抑制剂的单克隆抗体		
公开(公告)号	EP1675874A1	公开(公告)日	2006-07-05
申请号	EP2004817320	申请日	2004-07-29
[标]申请(专利权)人(译)	拜尔健康护理有限责任公司		
申请(专利权)人(译)	拜耳医药保健有限责任公司		
当前申请(专利权)人(译)	西门子医疗诊断INC.		
[标]发明人	PUGIA MICHAEL J ANDERSON MAUSER LINDA MURPHY SOLOMON H SOMMER RONALD G GLEASON SHANNON		
发明人	PUGIA, MICHAEL, J. ANDERSON-MAUSER, LINDA MURPHY, SOLOMON, H. SOMMER, RONALD, G. GLEASON, SHANNON		
IPC分类号	C07K16/38 G01N33/53 C07K16/18 G01N33/573		
CPC分类号	G01N33/573 C07K16/18 G01N2333/8107 G01N2333/811 G01N2333/976		
代理机构(译)	BURKERT , FRANK		
优先权	60/511835 2003-10-16 US		
外部链接	Espacenet		

摘要(译)

某些单克隆抗体能够检测出人类疾病特征的尿胰蛋白酶抑制剂 (UTI) 。特别地，UTI包括如本文所定义的AMBK，Bikunin，Uristatin，Uristatin-1，Uristatin-2，还包括其片段和聚集体。